Moderna Advances COVID-19 Vaccine Development
Summary from the AllSides News Team
Featured Coverage of this Story
From the Right
Moderna Receives $1.1B for Launch of Experimental COVID VaccineModerna Inc, one of the front-runners in the race to develop a vaccine for the new coronavirus, said on Thursday it was preparing to launch the experimental vaccine and had already received $1.1 billion in deposits for supply.
The Cambridge, Massachusetts-based company has signed deals with the U.S. government and several other countries, and is in talks with a WHO-led group for supply of the vaccine, which is in large, late-stage human trials.
While the company did not give a clear timeline on the release of data from these trials...
From the Center
Moderna says it's on track to report initial COVID-19 vaccine results next monthModerna is on track to report initial results from its coronavirus vaccine trial next month, company executives said Thursday.
The company is one of the front-runners to produce a vaccine for COVID-19. During an earnings call, Chief Medical Officer Tal Zaks said the trial is operating as planned, and an independent data-monitoring committee is expected to conduct an interim review in November.
The first review from the board will come after the trial reports that 53 cases of COVID-19 have been diagnosed among its sample, and the second interim analysis...
From the Left
Inside Operation Warp Speed’s $18 Billion Sprint for a VaccineOn a late August day in an industrial corner of Baltimore that had been mostly silenced by the pandemic, a red-brick manufacturing plant was buzzing with activity. Deep in the building, in a zone called Area 3, the stainless steel shell of a bioreactor lay on its side, having just arrived from Massachusetts. Employees had begun the task of making the bioreactor operational. Within weeks it would be the center of a production line for coronavirus vaccines.
AllSides Picks
March 28th, 2024
March 28th, 2024
March 27th, 2024